News & Updates

The addition of capivasertib to fulvestrant improves time to second progression (PFS2) and time to first subsequent chemotherapy or death (TTFSC) in PIK3CA/AKT1/PTEN-altered patients with HR+/HER2- advanced breast cancer and the overall population, suggesting a clinically meaningful benefit when compared with placebo plus fulvestrant, as shown in the phase III CAPItello-291 trial.

The 48-month analysis of the global phase III Clarity AD study shows that lecanemab continues to deliver benefit and delay progression in early Alzheimer's disease (AD).

Patients with rheumatoid arthritis (RA) who are living in areas with disadvantageous socioeconomic status (SES) appear to have higher disease activity, disability, and poorer quality of life (QOL), as shown in a study in Australia.